FDA Approves New Vivus ED Drug

Get ready for a whole new round of erectile dysfunction (ED) commercials. The Food and Drug Administration (FDA) has signed off on a new treatment for men facing bedroom issues.

The new ED drug, avanafil, developed by Vivus (NASDAQ:VVUS), will be marketed as Stendra in the U.S. and is even faster-acting than Pfizer‘s (NYSE:PFE) ever-popular Viagra.

Vivus shares were down nearly 3% in early Monday trading.

Stendra, the first new ED drug in a decade, joins a relatively crowded market. In addition to Viagra, other ED pills include Eli Lilly‘s (NYSE:LLY) Cialis and Bayer‘s (PINK:BAYRY) Levitra, which is distributed in the U.S. by GlaxoSmithKline (NYSE:GSK)

However, Stendra has an advantage over the competition. It has been shown to act within 15 minutes of ingestion, compared to Viagra, which can take about an hour. Additionally, it is expected to produce fewer side effects than existing ED medications.

An analyst cited by Reuters said Stendra could see annual sales of $300 million. While that’s a fraction of Viagra’s $2 billion in sales last year, it could provide a needed boost for Vivus, which is also betting on an anti-obesity drug, currently awaiting FDA approval.


Article printed from InvestorPlace Media, https://investorplace.com/2012/04/fda-approves-new-vivus-ed-drug/.

©2021 InvestorPlace Media, LLC